Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 7:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,345 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Aids Clear all
Completed Not applicable Interventional

Feasibility of an Exercise Intervention

NCT01984060
View directory record Official record
Conditions
HIV
Interventions
HOME-EX
Other
Lead sponsor
University of Rochester
Other
Eligibility
45 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 10, 2026, 7:09 AM EDT
Suspended Phase 1 Interventional

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

NCT06680479
View directory record Official record
Conditions
HIV-1
Interventions
CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 10, 2026, 7:09 AM EDT
Completed Phase 1 Interventional

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

NCT00001005
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 10, 2026, 7:09 AM EDT
Recruiting Phase 2 Interventional

Propranolol for the Treatment of Kaposi Sarcoma in Adults

NCT06445166
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
Propranolol Hydrochloride
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 10, 2026, 7:09 AM EDT
Completed Not applicable Interventional Results available

LinkPositively: A Technology-Delivered Peer Navigation and Social Networking Intervention to Improve HIV Care

NCT04199052
View directory record Official record
Conditions
HIV/AIDS
Interventions
LinkPositively
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 10, 2026, 7:09 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

NCT04652700
View directory record Official record
Conditions
HIV Preexposure Prophylaxis
Interventions
ISL, FTC/TDF, FTC/TAF, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 10, 2026, 7:09 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

NCT07525544
View directory record Official record
Conditions
HIV Infections
Interventions
VH4770359, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 10, 2026, 7:09 AM EDT
Completed Phase 1 Interventional

Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People

NCT02191098
View directory record Official record
Conditions
HIV, Stable ART
Interventions
ALT-803
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 10, 2026, 7:09 AM EDT
Completed Not applicable Interventional

A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

NCT00000914
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 10, 2026, 7:09 AM EDT
Terminated Phase 1 Interventional

Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00427414
View directory record Official record
Conditions
Sarcoma
Interventions
liposomal daunorubicin citrate
Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 10, 2026, 7:09 AM EDT
Completed Phase 1 Interventional

The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers

NCT01148004
View directory record Official record
Conditions
HIV, Fenofibrate, Protease Inhibitors, Hypertriglyceridemia, Glucuronosyltransferase
Interventions
Fenofibrate, Ritonavir, Lopinavir/Ritonavir
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 10, 2026, 7:09 AM EDT
Withdrawn No phase listed Observational

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women

NCT01394133
View directory record Official record
Conditions
HIV Infected
Interventions
Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Sep 10, 2026, 7:09 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

NCT01966367
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Schwachman Diamond Syndrome, Primary Immunodeficiency Syndromes, Acquired Immunodeficiency Syndromes, Histiocytic Syndrome, Familial Hemophagocytic Lymphocytosis, Lymphohistiocytosis, Macrophage Activation Syndrome, Langerhans Cell Histiocytosis (LCH), Hemoglobinopathies, Sickle Cell Disease, Sickle Cell-beta-thalassemia
Interventions
CD34 Stem Cell Selection Therapy
Biological
Lead sponsor
Diane George
Other
Eligibility
Up to 40 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 10, 2026, 7:09 AM EDT
Completed Phase 1 Interventional

The Effect of Stomach Acid on Foscarnet

NCT00000964
View directory record Official record
Conditions
HIV Infections
Interventions
Ranitidine hydrochloride, Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 10, 2026, 7:09 AM EDT
Completed Phase 1Phase 2 Interventional

A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients

NCT00036634
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir DF, Tenofovir alafenamide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
3
States / cities
Palo Alto, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Sep 10, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional

Comprehensive HIV and Harm Prevention Via Telehealth

NCT05897099
View directory record Official record
Conditions
HIV Infections
Interventions
Comprehensive Tele-harm Reduction, Off-site Linkage to HIV Prevention
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 10, 2026, 7:09 AM EDT
Completed Phase 2 Interventional

Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load

NCT00013663
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Sep 10, 2026, 7:09 AM EDT
Terminated Phase 4 Interventional Results available

Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults

NCT01791465
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection, Diabetes Mellitus
Interventions
extended-release exenatide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 10, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional

Community Health Workers And MHealth to ImProve Viral Suppression Plus (CHAMPS+)

NCT06472206
View directory record Official record
Conditions
HIV/AIDS
Interventions
CHW Sessions, CleverCap
Behavioral · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Hobson City, Alabama • Opelika, Alabama • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 10, 2026, 7:09 AM EDT
Completed Phase 1 Interventional

A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection

NCT00000652
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Months to 18 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 10, 2026, 7:09 AM EDT
Completed Not applicable Interventional

HIV Testing and Brief Alcohol Intervention for Young Drinkers in the Emergency Department

NCT01573065
View directory record Official record
Conditions
Alcohol Consumption, Sexual Risk Behaviors
Interventions
Counseling intervention with rapid HIV testing
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 10, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional

Pre-exposure Prophylaxis (PrEP) Adherence Intervention for Women with Substance Use Disorders

NCT06158607
View directory record Official record
Conditions
Substance Use
Interventions
Addiction Clinic-Based PrEP Adherence Intervention for Women with Substance Use Disorders, Standard of care treatment
Behavioral · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Sep 10, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention

NCT06005298
View directory record Official record
Conditions
Alcohol Use Disorder, Risk Behavior, Health, Dysbiosis, HIV Infections
Interventions
Screening, Brief Intervention, Referral to Treatment (SBIRT)
Behavioral
Lead sponsor
Shirish S Barve
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 10, 2026, 7:09 AM EDT
Completed No phase listed Observational

The Prevalence of Oral HPV Infection and Oral Lesions in People Living With HIV

NCT06205511
View directory record Official record
Conditions
Human Immunodeficiency Virus, Human Papilloma Virus
Interventions
Oral HPV Sample
Diagnostic Test
Lead sponsor
Vivent Health
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Denver, Colorado • St Louis, Missouri • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 10, 2026, 7:09 AM EDT